Cargando…

A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2

(1) Background: We previously reported the development of a recombinant protein SARS-CoV-2 vaccine, consisting of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, adjuvanted with aluminum hydroxide (alum) and CpG oligonucleotides. In mice and non-human primates, our wild-type (WT)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thimmiraju, Syamala Rani, Adhikari, Rakesh, Villar, Maria Jose, Lee, Jungsoon, Liu, Zhuyun, Kundu, Rakhi, Chen, Yi-Lin, Sharma, Suman, Ghei, Karm, Keegan, Brian, Versteeg, Leroy, Gillespie, Portia M., Ciciriello, Allan, Islam, Nelufa Y., Poveda, Cristina, Uzcategui, Nestor, Chen, Wen-Hsiang, Kimata, Jason T., Zhan, Bin, Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J., Pollet, Jeroen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610638/ https://www.ncbi.nlm.nih.gov/pubmed/37896960 http://dx.doi.org/10.3390/vaccines11101557

Ejemplares similares

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern
por: Pollet, Jeroen, et al.
Publicado: (2022)

Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2022)

Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1
por: Lee, Jungsoon, et al.
Publicado: (2021)

SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
por: Pollet, Jeroen, et al.
Publicado: (2021)

COVID-19 vaccines: neutralizing antibodies and the alum advantage
por: Hotez, Peter J., et al.
Publicado: (2020)

Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2021)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates
por: Pino, Maria, et al.
Publicado: (2021)

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
por: Faraone, Julia N., et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
por: Faraone, Julia N., et al.
Publicado: (2023)

Xbb subvariant of Omicron: Can the new wave sneak past your immune defense?
por: Hefnawy, Mahmoud T., et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
por: Wang, Qian, et al.
Publicado: (2023)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
por: Yang, Jingyun, et al.
Publicado: (2023)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
por: Ghosh, Shankhaneel, et al.
Publicado: (2023)

XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness
por: John, Okesanya Olalekan, et al.
Publicado: (2023)

Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as a Leishmania Vaccine Candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection
por: Versteeg, Leroy, et al.
Publicado: (2020)

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

XBB.1.5 emerges in the Americas: what it means to the region
por: Hotez, Peter
Publicado: (2023)

Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
por: Parums, Dinah V.
Publicado: (2023)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate
por: Chen, Wen-Hsiang, et al.
Publicado: (2017)

Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant
por: Karyakarte, Rajesh P, et al.
Publicado: (2023)

Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8(+) T-cells
por: Poveda, Cristina, et al.
Publicado: (2023)

Re-emergence of SARS-CoV-2 Omicron subvariant XBB.1.5: present status, treatment, and future outlook – 2023
por: Akash, Shopnil, et al.
Publicado: (2023)

Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response
por: Wei, Junfei, et al.
Publicado: (2017)

The hookworm Ancylostoma ceylanicum intestinal transcriptome provides a platform for selecting drug and vaccine candidates
por: Wei, Junfei, et al.
Publicado: (2016)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
por: Shah, Masaud, et al.
Publicado: (2023)

A commentary on ‘Re-emergence of SARS-CoV-2 Omicron subvariant XBB.1.5: present status, treatment, and future outlook – 2023’
por: Chiu, Si-Un Frank, et al.
Publicado: (2023)

Evolution of SARS CoV-2 Omicron subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID restrictions
por: Kelleni, Mina T.
Publicado: (2023)

Coronavirus vaccine-associated lung immunopathology-what is the significance?
por: Bottazzi, Maria Elena, et al.
Publicado: (2020)

The SARS-CoV-2 Vaccine Pipeline: an Overview
por: Chen, Wen-Hsiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tq9vc4ue186a568ebuia55q4fu